HDAC6 and neoplasm: The HDAC6 inhibitor ACY241 enhances the anti-tumor effects of antigen-specific CD8+ T cells by activating the AKT/mTOR/p65 pathways in solid tumors (Bae et al., 2018, Figure 5B).